| Literature DB >> 35632530 |
Martina Zanon1, Michela Peruch1, Monica Concato1, Carlo Moreschi2, Stefano Pizzolitto3, Davide Radaelli1, Stefano D'Errico1.
Abstract
BACKGROUND: in 2020, a new form of coronavirus spread around the world starting from China. The older people were the population most affected by the virus worldwide, in particular in Italy where more than 90% of deaths were people over 65 years. In these people, the definition of the cause of death is tricky due to the presence of numerous comorbidities.Entities:
Keywords: COVID-19; Geriatric Index of Comorbidity; autopsy; cause of death; frailty scores; long care term facilities; older people; strength of causation
Year: 2022 PMID: 35632530 PMCID: PMC9146610 DOI: 10.3390/vaccines10050774
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Definition of COVID-19-related death according to the Italian Istituto Superiore di Sanità (ISS).
| Strenght of Causation | Criteria #1 | Criteria #2 | Criteria #3 | Criteria #4 |
|---|---|---|---|---|
| Certain | The death occurred in a COVID-19 case (confirmed) | Clinical (fever, cough, dyspnoea, dizziness, etc.) and radiological features of COVID-19 infection | No other plausible cause of death other than COVID-19 infection | Lack of wellbeing among COVID-19 infection and the death |
| Probable | The death occurred in a COVID-19 case (probable) | Clinical (fever, cough, dyspnoea, dizziness, etc.) and radiological features of COVID-19 infection | No other plausible cause of death other than COVID-19 infection | Lack of wellbeing among COVID-19 infection and the death |
| Possible (suspect) | The death occurred in a COVID-19 case (suspect) | Clinical (fever, cough, dyspnoea, dizziness, etc.) and radiological features of COVID-19 infection | No other plausible cause of death other than COVID-19 infection | Lack of wellbeing among COVID-19 infection and the death |
Number of comorbidities and Geriatric Index of Comorbidity (GIC).
| Comorbidities (n) | Residents (%) |
|---|---|
|
| 15 |
|
| |
|
| 0 |
|
| 2 |
|
| 20 |
|
| 78 |
Distribution of swab results and Ct range.
| Nasopharingeal | Oropharingeal | Tracheal | Right Bronchus | Left Bronchus | Rectal | |
|---|---|---|---|---|---|---|
| Positive (n/%) | 24/58.5% | 25/61% | 26/63.4% | 28/68.3% | 25/61% | 4/10% |
| Negative (n/%) | 17/41.5% | 16/39% | 15/36.6% | 13/31.7% | 16/39% | 37/90% |
| Ct range | 15.47–37.11 | 17.64–36.35 | 18.08–35.45 | 19.69–36.7 | 16.65–36.56 | 32.62–35.72 |
| Ct < 23,99 (highly positive) | 9 | 14 | 8 | 7 | 9 | 0 |
| Ct 24–33,99 (moderately positive) | 14 | 9 | 16 | 16 | 11 | 2 |
| Ct > 34 (weakly positive) | 1 | 2 | 2 | 5 | 5 | 2 |
Strength of causation between COVID-19 infection and death.
| Strength of Causation of COVID-19 Infection | Characteristics | % |
|---|---|---|
| High (relevant to death) | ≥1 positive post mortem swab, signs of diffuse alveolar damage (DAD), with or without bacterial pneumonia, regardless of GIC class | 12% |
| Intermediate (contributing to death) | ≥1 positive post mortem swab, moderate signs of COVID-19 infection (e.g., interstitial lymphocytic infiltrates, type II pneumocyte hyperplasia, microthrombosis) with bacterial pneumonia and GIC class < IV | 10% |
| Low | ≥1 positive post mortem swab, moderate or no signs of COVID-19 infection (e.g., interstitial lymphocytic infiltrates, type II pneumocyte hyperplasia, microthrombosis), with or without bacterial pneumonia and GIC class IV | 59% |
| None | certain alternative cause of death, regardless of the outcome of the swab | 19% |